Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

This study is testing whether giving axitinib (a targeted therapy) plus a PD-1 immunotherapy drug before surgery can improve long-term outcomes for people with high-risk kidney cancer (renal cell carcinoma) that has not yet spread to distant organs. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with clear cell kidney cancer confirmed by biopsy or scan - Your cancer is staged as high-risk but still potentially removable (T2G4, T3–4, or lymph node involvement, without distant spread) - Your general health is good (ECOG performance status 0–1) - Your heart, blood, liver, and kidney functions are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have severe liver, kidney, or heart problems - You had a heart attack, blood clot, or stroke in the past year - You have uncontrolled high blood pressure or severe heart failure Talk to your doctor to see if this trial is right for you.